
Quarterly report 2025-Q3
added 11-13-2025
Acasti Pharma Net Debt 2011-2026 | ACST
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Acasti Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -27.4 M | -30 M | - | - | -15.5 M | -5.12 M | - | -2.23 M | -1.05 M | -607 K | -1.17 M | -1.6 M | -329 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -329 K | -30 M | -8.5 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Aclaris Therapeutics
ACRS
|
-22 M | $ 3.01 | 3.79 % | $ 233 M | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.1 | 1.31 % | $ 7.46 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 1.09 | -2.25 % | $ 5.94 M | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.95 | -1.27 % | $ 498 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 212.41 | 1.48 % | $ 5 B | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
BioVie
BIVI
|
-17.2 M | $ 1.14 | 0.49 % | $ 1.68 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 0.2 | 6.23 % | $ 435 M | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 94.97 | -0.33 % | $ 27.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 26.71 | -1.07 % | $ 1.29 B | ||
|
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 9.6 | 0.52 % | $ 141 M | ||
|
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Axon Enterprise
AXON
|
-404 M | $ 570.58 | -0.27 % | $ 43.2 B | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 11.67 | 0.56 % | $ 768 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.58 | 1.18 % | $ 16.2 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | $ 92.13 | -0.41 % | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 8.88 | -1.5 % | $ 1.46 B | ||
|
ChromaDex Corporation
CDXC
|
-26.5 M | - | -0.88 % | $ 598 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
455 M | $ 11.36 | -2.41 % | $ 735 M | ||
|
Biogen
BIIB
|
4.01 B | $ 176.12 | -0.16 % | $ 25.6 B | ||
|
Certara
CERT
|
119 M | $ 8.78 | -0.9 % | $ 1.41 B | ||
|
Cerevel Therapeutics Holdings
CERE
|
-33.6 M | - | - | $ 7.29 B |